Last reviewed · How we verify

Long Term Multiple Dose, Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of OXC XR as Adjunctive Therapy in Pediatric Subjects With Refractory Partial Epilepsy

NCT00918424 APPROVED_FOR_MARKETING

Follow-on study to continue evaluation of the safety of OXC XR as adjunctive therapy in pediatric epilepsy

Details

Lead sponsorSupernus Pharmaceuticals, Inc.
StatusAPPROVED_FOR_MARKETING
Start date2009-06

Conditions

Interventions

Countries

United States